The Health, Education, Labor and Pensions Committee today held the first in a series of hearings on how to reduce health care costs, which will examine administrative costs and waste, how to improve transparency, private sector solutions and other issues. Witnesses at today’s hearing included representatives from the Department of Health Policy at Vanderbilt University School of Medicine, Harvard Global Health Institute, Health Care Cost Institute and Georgetown University Law Center. In a statement submitted to the committee, AHA encouraged Congress to “pursue actions that will help reduce the cost of coverage without putting access to care at risk,” including addressing the high costs of prescription drugs, regulatory and administrative burden, and chronic disease, and “promoting enrollment in comprehensive health coverage to share costs across the broadest population possible.” While the share of national health expenditures for hospital care has declined and hospital price growth remains under 2%, spending for retail and inpatient prescription drugs have surged and hospitals “continue to provide a significant amount of uncompensated care,” increasingly because “individuals who have insurance cannot meet their high deductibles and other cost-sharing requirements,” the statement notes.

Related News Articles

Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…